 |
13 Companies | 15 Products |
|
|
15 Products | |
46 Diseases | |
8 Trials |  |
488 News |  |
| «12...567891011121314151617» |
- Clinicopathologic Analysis of Myeloid Sarcoma with Megakaryocytic Differentiation: Case Series and Review of the Literature (LACC West Exhibit Hall A, Poster Board Number: 268) - Jan 24, 2020 - Abstract #USCAP2020USCAP_2143;
Comparing to MS without megakaryocytic differentiation as described in the WHO Classification, MS with megakaryocytic differentiation tends to present with multiple lesions, is more often associated with MPN, and shows much worse prognosis.
- Targetable Markers May Be Differentially Expressed by Flow Cytometry in Peripheral Blood and Bone Marrow Blasts in Acute Leukemias (LACC West Exhibit Hall A, Poster Board Number: 267) - Jan 24, 2020 - Abstract #USCAP2020USCAP_2142;
Most commonly, this occurred with CD123 but was observed in other Ags such as CD20, CD22, and CD33. Our data support analyses across specimens for ALs and may be particularly critical in an era of targeted therapy for ALs.
- | Journal: Somatostatin Receptor Subtype-4 Regulates mRNA Expression of Amyloid-Beta Degrading Enzymes and Microglia Mediators of Phagocytosis in Brains of 3xTg-AD Mice. (Pubmed Central) - Jan 22, 2020
No changes in pro-inflammatory cytokine expression were found. These data demonstrated NNC 26-9100 facilitates transcriptional changes in brain tissue identified with Aβ phagocytosis and clearance, further supporting SSTR as a treatment target for AD.
- Primary Histiocytic Sarcoma of the Central Nervous System: A case report with an unusual initial presentation and rapid progression () - Jan 21, 2020 - Abstract #AAN2020AAN_3106;
This case presentation has qualities supporting further discussion regarding its potential for misdiagnosis and highlights the rapid progression of the disease process despite relatively benign symptoms at onset. Primary HS of the CNS should be considered as a possible cause of sudden onset of lower back pain progressing rapidly to weakness of the lower extremities bilaterally in addition to multiple cranial nerve impairments.
- | Journal: The CD33 genotype associated cognitive performance was bidirectionally modulated by intrinsic functional connectivity in the Alzheimer's disease spectrum. (Pubmed Central) - Jan 16, 2020
Furthermore, gFCD in the dorsal anterior cingulate cortex positively mediated the relationship between the CD33 genotype and cognition, while gFCD in the precuneus bidirectionally moderated the mediation in the AD spectrum. These findings provide new insights into the neural mechanisms underlying the influence of the CD33 genotype on cognitive performance and highlight the importance of precise therapeutic strategies for high-risk AD populations.
- Predictors of Relapse after Haploidentical Hematopoietic Progenitor Cell Transplantation (Haplo-HCT); A Single-Institution Experience (World Center Marriott - Palms & Cypress Foyers) - Jan 14, 2020 - Abstract #TCTASTCTCIBMTR2020TCT_1236;
Complete CD3 and CD33 donor chimerisms at D30 and D100 predict a patients risk for relapse following haplo-HCT. We observed a strong association between CD3 chimeric status at D30 with DRI, as well suggestive that high risk disease may be associated with impaired immune reconstitution after transplant and perhaps a less robust graft vs disease effect.
- cyclophosphamide intravenous / Generic mfg.
High Incidence of Mixed T Cell Chimerism with Reduced Toxicity Conditioning Regimens in Non-Malignant Diseases Are Not Associated with Adverse Outcomes (World Center Marriott - Palms & Cypress Foyers) - Jan 14, 2020 - Abstract #TCTASTCTCIBMTR2020TCT_1026;
In our cohort we have shown that in the majority of patients without pursuing DLI or a CD34 cell boost or changes in immune suppression, T cell chimerism continues to improve provided a robust myeloid graft. Patients with mixed T cell chimerism have an excellent survival rate, without increased second graft loss, GVHD, or viral reactivation.
- Chimeric Antigen Receptor T Cell Therapy for Acute Myeloid Leukemia (World Center Marriott - Palms & Cypress Foyers) - Jan 14, 2020 - Abstract #TCTASTCTCIBMTR2020TCT_946;
Finally, to find the best combination of CARs that would be less toxic to HSCs, we performed a Colony Forming Unit (CFU) assay with CD34+ bone marrow stem cells and found 5 bi-specific pairs that were less toxic to HSCs . Based on the CFU assay and PSI index, we were able to select the combination of CD33/123 scFvs that would target AML but minimize the killing of HSCs.
- | Preclinical, Journal: Repression of phagocytosis by human CD33 is not conserved with mouse CD33. (Pubmed Central) - Jan 13, 2020
Moreover, transgenic mice expressing hCD33 in the microglial cell lineage showed repressed cargo uptake in primary microglia. Therefore, mCD33 and hCD33 have divergent roles in regulating phagocytosis, highlighting the importance of studying hCD33 in AD susceptibility.
- | Journal: Curcumin restores innate immune Alzheimer's disease risk gene expression to ameliorate Alzheimer pathogenesis. (Pubmed Central) - Jan 11, 2020
Like curcumin, anti-Aβ antibody (also reported to engage the Syk pathway, increase CD68, and decrease amyloid burden in human and mouse brain) increased TREM2 in APPsw mice and decreased amyloid in human AD sections ex vivo. We conclude that curcumin is an immunomodulatory treatment capable of emulating anti-Aβ vaccine in stimulating phagocytic clearance of amyloid by reducing CD33 and increasing TREM2 and TyroBP, while restoring neuroinflammatory networks implicated in neurodegenerative diseases.
- [VIRTUAL] A HUMAN ESC-DERIVED MICROGLIA MULTIOMIC AND FUNCTIONAL PLATFORM REVEALS CONVERGENT PATHOGENIC POTENTIAL FOR ALZHEIMER’S VARIANTS (Hall N) - Jan 6, 2020 - Abstract #AATADPD2020AAT_ADPD_361;
Conclusions In conclusion, these results reveal distinct epigenetic and expression characteristics in various AD-associated hMGLs, and demonstrate new epistatic relationships between microglial AD-risk genes. This provides an analytical platform to evaluate cross-regulatory expression and functional relationships between elusive AD risk variants.
- [VIRTUAL] Microglial ITAM and ITIM Immunoreceptors as Therapeutic Targets for Alzheimer's Disease (Hall F2) - Jan 6, 2020 - Abstract #AATADPD2020AAT_ADPD_303;
Conclusions Our results suggest that TREM2 activity may be protective in both the early, β-amyloidogenic stage of AD and the later stages involving tau spreading and neurodegeneration. Our Pilra and Cd33 studies, and our characterization of human AD microglia, highlight the need for improved models of AD pathogenesis with better conservation of human microglial biology.
- AL003 / Alector, AbbVie
[VIRTUAL] A PHASE 1 STUDY OF AL003, AN ANTI-SIGLEC 3 ANTIBODY, IN HEALTHY VOLUNTEERS AND PATIENTS WITH MILD-TO-MODERATE ALZHEIMER’S DISEASE (Hall F1) - Jan 6, 2020 - Abstract #AATADPD2020AAT_ADPD_8;
Conclusions To date, AL003 appears to have an acceptable safety profile and to engage the target receptor. It is being considered for investigation in a proof-of-concept Phase 2 study.
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Review, Journal: Novel monoclonal antibody-based therapies for acute myeloid leukemia. (Pubmed Central) - Jan 4, 2020
Over the last several years, work to improve the success of monoclonal antibody-based therapies in AML has focused on the identification and exploration of new antigen targets as much as on the development of novel treatment formats such as use of unconjugated engineered monoclonal antibodies and conjugated antibodies, delivering highly potent small molecule drugs or radionuclides to AML cells. Here, we will provide a brief overview of current efforts with such investigational monoclonal antibody-based therapeutics.
- | Venclexta (venetoclax) / Roche, AbbVie
Review, Journal: Venetoclax-based therapies for acute myeloid leukemia. (Pubmed Central) - Jan 4, 2020
Clinical trials have demonstrated the clinical benefit of venetoclax-based therapies in newly diagnosed AML, leading to the recent FDA approval of venetoclax in combination with hypomethylating agents or low-dose cytarabine for older adults with newly diagnosed AML. Herein, we focus on the role of single-agent BCL-2 inhibition in AML and review the clinical studies of venetoclax-based combination regimens and the evolving mechanisms of resistance.
- | Clinical, Journal: CML with Megakaryocytic Blast Crisis: Report of 3 Cases. (Pubmed Central) - Jan 1, 2020
The diagnosis of such rare presentation of CML is essential for determining the choice of treatment. Therefore including a megakaryocytic marker in the primary flow cytometry panel is important so that these cases are not under-diagnosed as Acute myeloid leukemia because of expression of CD13 and CD33 only.
- ||||| CAR T-Cell Therapy: *extramural CAR T cell projects They are spending a lot to support the NIH owned CAR T cell inventions, like the CD33 CAR that’s available for licensure. (Twitter) - Dec 31, 2019
- || Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Clinical, Journal: Clinical and Radiographic Response of Extramedullary Leukemia in Patients Treated With Gemtuzumab Ozogamicin. (Pubmed Central) - Dec 28, 2019
Here we present 2 patients with CD33 EML treated with GO. They achieved significant response, with reduction of EML on both clinical and radiographic exams, specifically fluorine fluorodeoxyglucose positron emission tomography/computed tomography, demonstrating potential for targeted therapy with GO as a means of treating EML in patients with CD33 leukemia and the utility of fluorine fluorodeoxyglucose positron emission tomography/computed tomography monitoring in EML.
- || imatinib / Generic mfg.
Clinical, Journal: Demographics and Outcome of Philadelphia-positive ALL in a Pediatric Population in North India: a Single-center Experience. (Pubmed Central) - Dec 28, 2019
Overall survival was similar in Ph+ and Ph- high-risk ALL patients. Ph+ ALL, noted in 7.28%, presented with high initial white blood cell counts, high central nervous system positivity, poor steroid response, and higher induction deaths, as compared with high-risk Ph- ALL, and raised the question about the appropriate dose and time of introduction of imatinib to prevent toxicity.
- || Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Clinical, FDA event, Journal: FDA Approval: Gemtuzumab ozogamicin for the treatment of adults with newly-diagnosed CD33-positive acute myeloid leukemia. (Pubmed Central) - Dec 24, 2019
Adverse events were similar on both arms. Post-approval, several studies are required including evaluation of fractionated GO pharmacokinetics, safety of combination GO in the pediatric population, of immunogenicity, and of the effects of GO on platelet function.
- | Journal: Detection of CD33 expression on monocyte surface is influenced by phagocytosis and temperature. (Pubmed Central) - Dec 23, 2019
After exposure to E. coli the CD33 relative fluorescence intensity of the monocytes activated at 37°C was 3 to 4 times higher than that of those cells kept inactive at 0°C. Microscopic analysis showed internalisation of CD33 due to its enhanced expression on the surface followed by engulfment of E. coli.
- Imbruvica (ibrutinib) / AbbVie, J&J
Association of myeloid suppressor cells with resistance to checkpoint blockade immunotherapy in urothelial carcinoma. (Poster Board L18) - Dec 22, 2019 - Abstract #ASCOGU2020ASCO_GU_1294;
Analysis of MDSC from patients with bladder cancer suggests that these myeloid suppressor cells can be specifically targeted. Research Funding: American Urological Association - Urology Care Foundation.
- Imbruvica (ibrutinib) / AbbVie, J&J
Association of myeloid suppressor cells with resistance to checkpoint blockade immunotherapy in urothelial carcinoma. (Poster Board L18) - Dec 22, 2019 - Abstract #ASCOGU2020ASCO_GU_1012;
Analysis of MDSC from patients with bladder cancer suggests that these myeloid suppressor cells can be specifically targeted. Research Funding: American Urological Association - Urology Care Foundation.
- || methylprednisolone oral / Generic mfg.
Clinical, Journal, Myeloid-derived suppressor cells: Myeloid-Derived Suppressor Cells Increase and Inhibit Donor-Reactive T Cell Responses to Graft Intestinal Epithelium in Intestinal Transplant Patients. (Pubmed Central) - Dec 21, 2019
IL-6 and methylprednisolone enhanced the differentiation of bone marrow cells to MDSCs in vitro...A novel in vitro assay demonstrated that MDSCs suppressed donor-reactive T-cell-mediated destruction of donor intestinal epithelial organoids. Taken together, our results suggest that MDSCs accumulate in the recipient PBMCs and the grafted intestinal mucosa in ITx, and may regulate ACR.
- New strategy for the treatment of acute myeloid leukemia by combining specific CD33 tumor targeting with CD47-SIRPa immune checkpoint blockade () - Dec 21, 2019 - Abstract #ITOC2020ITOC_159;
- | Journal: CD33 (Siglec-3) Inhibitory Function: Role in the NKG2D/DAP10 Activating Pathway. (Pubmed Central) - Dec 20, 2019
CD33-mediated inhibition of NKG2D-induced triggering involved Vav1 dephosphorylation. Our results support the role of CD33 as an inhibitory receptor preferentially regulating the NKG2D/DAP10 cytotoxic signaling pathway, which could be involved in self-tolerance and tumor and infected cell recognition.
- || Review, Journal: What is recommended in the treatment of acute myeloid leukemia? (Pubmed Central) - Dec 19, 2019
Among these drugs are the Bcl‑2 inhibitor venetoclax, which is already approved in Germany for chronic lymphatic leukemia, as well as IDH1/IDH2 inhibitors (the latter for patients with IDH1/IDH2 mutated AML). Acute promyelocytic leukemia represents a special type of AML that should be treated with a combination of all-trans retinoic acid and arsenic trioxide leading to excellent outcome.
- Graft-Versus-Host Disease after Solid Organ Transplant Is Frequently Associated with Bone Marrow Failure and Hemophagocytosis (World Center Marriott - Palms & Cypress Foyers) - Dec 18, 2019 - Abstract #TCTASTCTCIBMTR2020TCT_791;
Marrow but not peripheral blood donor CD3 chimerisms are prognostic for BMF. Identification of HLH features may guide prognosis and therapeutics in these patients.
- | Preclinical, Journal: Repression of phagocytosis by human CD33 is not conserved with mouse CD33. (Pubmed Central) - Dec 10, 2019
Moreover, transgenic mice expressing hCD33 in the microglial cell lineage showed repressed cargo uptake in primary microglia. Therefore, mCD33 and hCD33 have divergent roles in regulating phagocytosis, highlighting the importance of studying hCD33 in AD susceptibility.
- || #ASH19 #bmtsm Rovatti: CD33-CD3 bispecific directs T cell activity against HLA loss variants (Twitter) - Dec 8, 2019
- | Journal: Association of MS4A6A, CD33, and TREM2 gene polymorphisms with the late-onset Alzheimer's disease. (Pubmed Central) - Dec 8, 2019
Therefore, mCD33 and hCD33 have divergent roles in regulating phagocytosis, highlighting the importance of studying hCD33 in AD susceptibility. The evidence from the present study suggests that T allele of CD33 rs3865444 polymorphism is associated with LOAD in the studied Iranian population.
- fludarabine / Generic mfg.
An Anti-CD300f Antibody Drug Conjugate Depletes Hematopoietic Stem Cells and Primary Acute Myeloid Leukemia (AML): Facilitating a Targeted Conditioning Regimen for Allogeneic Stem Cell Transplantation in AML (World Center Marriott - Palms: Sabal) - Dec 8, 2019 - Abstract #TCTASTCTCIBMTR2020TCT_652;
The ADC synergises with fludarabine, making it a natural combination to use in a minimal toxicity conditioning regimen...We have demonstrated that our ADC prolongs survival in mouse cell line models as well as depletes both HSPC and primary AML in vivo. A targeted conditioning agent has the potential to reduce relapse risk and toxicity of allo-HSCT in AML.
- || Clinical, Journal: Clinical-biological characteristics and treatment outcomes of pediatric pro-B ALL patients enrolled in BCH-2003 and CCLG-2008 protocol: a study of 121 Chinese children. (Pubmed Central) - Dec 8, 2019
Pediatric pro-B ALL is a heterogeneous disease. Genetic analysis and MRD evaluation can predict patients with dismal prognosis; however, intensive chemotherapy alone does not improve outcomes of these patients and targeted therapy or hematopoietic stem cell transplantation may be required.
- | Biomarker, Journal, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: Cancer biomarkers for targeted therapy. (Pubmed Central) - Dec 8, 2019
To reduce and avoid off-tumor toxicities, cancer-specific TAAs such as CD33 are being manufactured through systems biology approach. Search for novel biomarkers and new designs as well as delivery methods of targeted agents are fueling the next wave of advances in cancer therapy.
- | Journal, PD(L)-1 Biomarker, IO Biomarker: Cytometry TOF identifies alveolar macrophage subtypes in acute respiratory distress syndrome. (Pubmed Central) - Dec 6, 2019
In an independent cohort of subjects with ARDS, PD-L1 gene expression and PD-L1/PD-1 pathway-associated gene sets were significantly decreased in AMs from patients who experienced prolonged mechanical ventilation or death. Unsupervised CyTOF analysis of alveolar leukocytes from human subjects has potential to identify expected and potentially novel myeloid populations that may be linked with clinical outcomes.
- | Journal: Translating Alzheimer's disease-associated polymorphisms into functional candidates: a survey of IGAP genes and SNPs. (Pubmed Central) - Nov 30, 2019
The IGAP SNPs in ABCA7, CD2AP, and CD33 each acted as eQTL for AD-associated genes in brain. Our approach for identifying proxies and examining eQTL highlighted potentially impactful, novel gene regulatory phenomena pertinent to the AD phenotype.
- || Clinical, Journal, IO Biomarker: Correlation analysis between LINC00324 and immunophenotype in peripheral blood leukocytes in patients with acute myeloid leukemia (Pubmed Central) - Nov 29, 2019
The expression of LINC00324 in AML patients was associated with multiple immunophenotypes such as CD33, CD117, CD11b, CD14 and CD64 and was negatively correlated with peripheral blood blast percentage and white blood cell count. Conclusion LINC00324 may be involved in regulating the differentiation, development and function of immune cells, which providing a new strategy for the development of targeted drugs or treatment of AML.
- IL-17 and Th17 in melanoma outcome () - Nov 21, 2019 - Abstract #SMR2019SMR_231;
Our studies affirm a difference between IL-17 expression and Th17 cells in melanoma patients. The high degree of plasticity, known to occur in Th17 cells, is likely an important factor, and may be exploited for synergy with immunotherapy.
- | Clinical, Journal: Clinical Features and Prognosis of 188 Patients with Acute Myeloid Leukemia-M (Pubmed Central) - Nov 18, 2019
The high degree of plasticity, known to occur in Th17 cells, is likely an important factor, and may be exploited for synergy with immunotherapy. The clinical characteristics are different between M patients with different karyotype, and prognostic analysis shows that the karytypes have an impact on overall survival; age, extramedullary infiltration, CD19 expression and CEBPA double mutation are also the main factors impacting the prognosis of patients.
- || Flow on the AML showed 75.3% myeloblasts expressing CD7, CD11b, CD13, CD33, CD34, CD38, CD45, CD117(dim), CD123, HLA-DR, and MPO (Twitter) - Nov 14, 2019
- | Journal: Whole-exome sequencing of the BDR cohort: Evidence to support the role of the PILRA gene in Alzheimer's disease. (Pubmed Central) - Nov 11, 2019
The clinical characteristics are different between M patients with different karyotype, and prognostic analysis shows that the karytypes have an impact on overall survival; age, extramedullary infiltration, CD19 expression and CEBPA double mutation are also the main factors impacting the prognosis of patients. In addition, polygenic risk scores (PRS) were able to distinguish between cases and controls with 83.8% accuracy using 3,268 variants, sex, age at death and APOE ε4 and ε2 status as predictors.
- || Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Clinical, Review, Journal: Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia. (Pubmed Central) - Nov 7, 2019
In addition, several novel ADCs targeting CD33, CD123 and CLL-1 are currently undergoing preclinical or early clinical investigations. In this review, we summarized the efficacy and limitations of GO as well as novel ADCs for adult AML patients.
- Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Novel CD33 Antibodies Unravel Localization, Biology, and Therapeutic Implications of CD33 Isoforms (W308, Level 3 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_6574;
Subsequent staining with P67.6 only produced a positive signal in BaF3-CD33FLGFP cells while BaF3-CD33D2GFP, which lack the IgV domain, were negative (Figure 2B) . Interestingly both novel IgC targeting antibodies, 5C11-2 and HL2541, only stained positive for BaF3-CD33D2GFP cells and were negative for BaF3-CD33FL cells (Figure 2C) .
- Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_6210;
P2
Secondary outcomes will include survival, both progression-free (PFS) and overall (OS) until two years post treatment, and dose limiting toxicities until 16 weeks post-infusion . Additional lab correlative studies will be performed including CD33 expression before, during, and after GO infusion and T-cell activation markers, antigen presenting cell/macrophage amounts, cytokine release profiles, and extracellular vesicle measurements (Figure 1).
- azacitidine / Generic mfg.
Use of CD70 Targeted Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML) (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_6192;
Combination treatment with azacitidine may increase target antigen expression and lead to synergistic activity and represents a viable therapeutic strategy that warrants further investigation. Treatment of AML engrafted NSG mice with CD70 CAR-T cells in conjunction with azacitidine is ongoing.
- AMG 330 / Amgen
CRISPR/Cas9-Mediated Protection of Normal Hematopoiesis Combined with the CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody AMG330 for Improved AML Therapy (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_6175;
B) Quantification of CD14+/CD33+ and CD14+/CD33− cells from peripheral blood of AMG330-treated animals in Cas9 only (n=3) and CRISPR/Cas9 (n = 3) groups . In A) and B), ‘pre’ is before AMG330 treatment and ‘post’ is 5 days after administration.
- High-Throughput RNA Sequencing Analysis Reveals Distinct Molecular Signature in NRAS and PTPN11 JMML Patients (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_5971;
Differences in the expression of microRNAs subsets, LIN28B and subunits of the HbA and HbF already described in JMML, but here related to specific mutations and cell lineages, could help to better understand the pathogenic processes and peculiar clinical behaviors . Finally, the novel evidence of differential RNA editing in JMML opens new perspectives for further studies regarding differential protein isoforms expression and regulation as well as microRNA targeting.
- Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML) (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_5965;
To confirm the clinical relevance of expression of surface target antigens on CMML LSC, we applied the CD33-targeted drug gemtuzumab-ozogamicin (GO)...During progression of CMML into sAML, LSC apparently acquire CD25 . Characterization of CMML LSC and LSC in sAML should facilitate their enrichment and the development of LSC-eradicating therapies.
- Altered Dynamics of Monocyte Subpopulations and Pro-Inflammatory Signaling Pathways in Polycythemia Vera Revealed By Mass Cytometry (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_5951;
To our knowledge NFkB has not previously been investigated in PV . This study suggests that NFkB signaling is similarly important to PV and might play a role in disease transformation .
- Mass Cytometry Identifies a Novel Signature for Myeloid-Derived Suppressor-Cells in Waldenstrom’s Macroglobulinemia (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_5708;
Furthermore, MDSCs in the BM of WM patients suppress T-cell function and likely contribute to progression of the disease . MDSCs in the BM therefore present a therapeutic target that should be explored in WM patients.